The case for & against
Bull & Bear analysis
Bullish
Agilent Technologies, Inc. (NYSE: A) is a leading company in the life sciences, diagnostics, and applied chemical markets, providing high-value analytical solutions through instruments, software, services, and consumables. The company has established a strong market presence, particularly through its recent innovations and acquisitions including the purchase of Biocare Medical, positioning itself to capitalize on growth trends in pharmaceuticals and diagnostics.
Bull says
- ↑Q2 revenue $1.83B (+6.3% YoY) across diversified end markets.
- ↑Operating margin 26.4% (+130bps YoY) enabled by Ignite efficiencies.
- ↑Biocare Medical acquisition expands cancer diagnostics portfolio.
- ↑FY26 revenue guidance +4.5–6% with EPS $6.00–6.10.
- ↑High earnings yield and strong profitability indicate undervaluation.
- ↑Positive analyst revisions and solid leverage support growth outlook.
Bear says
- ↓Tariffs expected to reduce margins by ~200 bps, raising costs.
- ↓Academic/government sales low single-digit growth; recovery uncertain.
- ↓Elevated short interest and cautious institutional ownership linger.
- ↓Weak price momentum may pressure near-term stock performance.
- ↓Low dividend yield and poor liquidity concern income investors.
- ↓Negative analyst revisions and low 13F ownership fuel caution.
Investment themes with A
SPY↑ +0.09%
NVDA · AAPL · GOOGL
Medical Devices↑ +0.44%
Devices and instruments for medical treatment
MEDP · RDNT · OPCH
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 05-27-2026bullish
Transcript signals
Bull points
- Agilent's conference call for the second quarter of fiscal year 2025
Read full transcript analysis ›